Bausch + Lomb (NYSE:BLCO) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Bausch + Lomb (NYSE:BLCO) released its quarterly earnings results on Wednesday. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.23 by $0.02, Zacks reports. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. Bausch + Lomb updated its FY 2025 guidance to EPS.

Bausch + Lomb Stock Up 0.7 %

BLCO stock traded up $0.12 during mid-day trading on Wednesday, hitting $16.47. The stock had a trading volume of 195,314 shares, compared to its average volume of 629,466. The company has a current ratio of 1.57, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69. Bausch + Lomb has a 1-year low of $13.16 and a 1-year high of $21.69. The company has a fifty day moving average of $17.51 and a 200 day moving average of $18.16. The stock has a market capitalization of $5.80 billion, a price-to-earnings ratio of -15.60, a PEG ratio of 2.17 and a beta of 0.46.

Analysts Set New Price Targets

A number of equities analysts have issued reports on BLCO shares. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Bausch + Lomb in a research report on Tuesday. Bank of America reaffirmed an “underperform” rating and issued a $18.00 target price on shares of Bausch + Lomb in a research report on Thursday, December 12th. Morgan Stanley lowered Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 target price on the stock. in a research report on Monday, December 2nd. Citigroup downgraded Bausch + Lomb from a “buy” rating to a “neutral” rating and lowered their price target for the company from $24.00 to $22.00 in a report on Wednesday, December 11th. Finally, Wells Fargo & Company lowered their price target on Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, January 16th. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $20.25.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.